SCHEMBL7862169

SCHEMBL7862169

CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CCC(=O)NCCC[C@@H](C(=O)NC2CC2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 15/20 0.62
▸ TUBB4A P04350 3/20 0.60
▸ TUBB P07437 3/20 0.60
▸ TUBA3C P0DPH7 3/20 0.60
▸ TUBA1B P68363 3/20 0.60
▸ TUBA4A P68366 3/20 0.60
▸ TUBB4B P68371 3/20 0.60
▸ TUBB3 Q13509 3/20 0.60
▸ TUBB2A Q13885 3/20 0.60
▸ TUBB8 Q3ZCM7 3/20 0.60
▸ TUBA3E Q6PEY2 3/20 0.60
▸ TUBA1A Q71U36 3/20 0.60
▸ TUBA1C Q9BQE3 3/20 0.60
▸ TUBB6 Q9BUF5 3/20 0.60
▸ TUBB2B Q9BVA1 3/20 0.60
▸ TUBB1 Q9H4B7 3/20 0.60
▸ MC1R Q01726 7/20 0.54
▸ MC5R P33032 3/20 0.54
▸ MC3R P41968 3/20 0.54
▸ TSLP Q969D9 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18716985 1.00 MC4R (0.62) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18716918 1.00 MC4R (0.62) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18716928 0.96 MC4R (0.62) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18716884 0.96 MC4R (0.62) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10089230 0.96 MC4R (0.62) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18717067 0.95 MC4R (0.64) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL7865914 0.95 MC4R (0.68) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18717060 0.95 MC4R (0.64) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18717174 0.95 MC4R (0.68) MC4RTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL18716852 0.95 MC4R (0.68) MC4RTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632171-B2 Melanocortin receptor-specific peptides PALATIN TECHNOLOGIES, INC. (US) 2020-04-28 — — US disclosed
US-20190216887-A1 Melanocortin Receptor-Specific Peptides PALATIN TECHNOLOGIES INC (US) 2019-07-18 — — US disclosed
US-10179804-B2 Melanocortin receptor-specific peptides PALATIN TECHNOLOGIES, INC. (US) 2019-01-15 — — US disclosed
EP-2440572-B1 LACTAM-BRIDGED MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES PALATIN TECHNOLOGIES INC (US) 2017-04-05 — — EP disclosed
US-20160318977-A1 Melanocortin Receptor-Specific Peptides PALATIN TECHNOLOGIES INC (US) 2016-11-03 — — US disclosed
US-9458201-B2 Melanocortin receptor-specific heptapeptides PALATIN TECHNOLOGIES, INC. (US) 2016-10-04 — — US disclosed
US-9273098-B2 Lactam-bridged melanocortin receptor-specific peptides PALATIN TECHNOLOGIES, INC. (US) 2016-03-01 — — US disclosed
US-20140357575-A1 Melanocortin Receptor-Specific Heptapeptides PALATIN TECHNOLOGIES INC (US) 2014-12-04 — — US disclosed
US-8846601-B2 Melanocortin receptor-specific peptides PALATIN TECHNOLOGIES, INC. (US) 2014-09-30 — — US disclosed
US-20120178701-A1 Melanocortin Receptor-Specific Peptides PALATIN TECHNOLOGIES, INC. (US) 2012-07-12 — — US disclosed
US-20120077957-A1 Lactam-Bridged Melanocortin Receptor-Specific Peptides PALATIN TECHNOLOGIES, INC. (US) 2012-03-29 — — US disclosed
WO-2010144341-A2 LACTAM-BRIDGED MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2010-12-16 — — WO disclosed
WO-2010144344-A2 MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077957-A1 Lactam-Bridged Melanocortin Receptor-Specific Peptides MC1R, MC3R, MC4R MC4R 3/4885TUBB4A 3074/4885TUBB 2518/4885
US-10179804-B2 Melanocortin receptor-specific peptides MC1R, MC3R, MC5R MC4R 4/4885TUBB4A 4677/4885TUBB 4534/4885
US-20140357575-A1 Melanocortin Receptor-Specific Heptapeptides MC5R, MC1R, MC3R MC4R 5/4885TUBB4A 4580/4885TUBB 4839/4885
US-20190216887-A1 Melanocortin Receptor-Specific Peptides MC1R, MC3R, MC4R MC4R 3/4885TUBB4A 4235/4885TUBB 4136/4885
US-20160318977-A1 Melanocortin Receptor-Specific Peptides MC1R, MC3R, MC5R MC4R 4/4885TUBB4A 4677/4885TUBB 4534/4885
US-10632171-B2 Melanocortin receptor-specific peptides MC1R, MC3R, MC4R MC4R 3/4885TUBB4A 4235/4885TUBB 4136/4885
US-20120178701-A1 Melanocortin Receptor-Specific Peptides MC1R, MC3R, MC5R MC4R 4/4885TUBB4A 4677/4885TUBB 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback